Welcome to HitGen

Capabilities

One-stop Technology Platform to Accelerate Drug Discovery and Development

  1. Capabilities
  2. Fragment Screening

Fragment Screening

Fragment-based discovery identifies low molecular weight molecules which make key interactions with their target binding site. Fragments provide a range of efficient starting points from which potent ligands, and eventually drugs, can be developed. 


Traditional fragment screening

Over the past decade, Vernalis has developed its proprietary library of fragments, successfully applied to more than 20 targets. Our library is typically screened using NMR spectroscopy, with the structure of bound fragments determined by X-ray crystallography (Hubbard, R. E. et al., Curr. Top. Med. Chem. 2007).


Fragment DEL screening

Fragment DEL Screening combines its sensitivity in DNA sequences and linker photo-labeling to extend its application to fragment discovery. HitGen Fragment DEL consists of >30,000 fragments and the selection inherit DEL selection efficiency and cost effectiveness. 

For more details, please refer to Fragment DEL Selection

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information